Malignant triton tumor

Malignant triton tumor (MTT) is an extremely rare and aggressive subtype of malignant peripheral nerve sheath tumor (MPNST) that is distinguished by the presence of rhabdomyoblastic (skeletal muscle) differentiation within the tumor. This means the tumor arises from cells of the peripheral nerve sheath but also contains malignant cells showing features of striated muscle. MTT primarily affects the peripheral nervous system and surrounding soft tissues, and can occur in virtually any anatomical location where peripheral nerves are found, including the extremities, trunk, head, and neck. A significant proportion of cases arise in patients with neurofibromatosis type 1 (NF1), often developing within pre-existing plexiform neurofibromas, though sporadic cases and cases associated with prior radiation therapy have also been reported. Key symptoms depend on the tumor's location but typically include a rapidly enlarging, often painful soft tissue mass. Neurological deficits such as numbness, weakness, or tingling may occur if the tumor compresses or invades adjacent nerves. Patients with NF1 who notice sudden rapid growth of a pre-existing neurofibroma should be evaluated urgently, as this may signal malignant transformation. The tumor is known for its highly aggressive behavior, with a strong tendency for local recurrence and distant metastasis, most commonly to the lungs. The prognosis for malignant triton tumor is generally poor, with reported five-year survival rates significantly lower than those for conventional MPNST. Treatment typically involves wide surgical excision with clear margins as the primary approach. Adjuvant radiation therapy is frequently employed to reduce local recurrence, and chemotherapy (often using doxorubicin-based regimens similar to those used for other soft tissue sarcomas) may be considered, particularly in cases of metastatic or unresectable disease, though its efficacy remains limited. Due to the rarity of this tumor, there are no standardized treatment protocols, and management is generally guided by multidisciplinary sarcoma teams. Clinical trials investigating novel targeted therapies and immunotherapies for MPNST subtypes are ongoing areas of research.

Common questions about Malignant triton tumor